Aytu Biopharma, Inc.
AYTU
$2.17
-$0.04-1.81%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -17.98% | 13.75% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -17.98% | 13.75% | |||
| Cost of Revenue | -13.55% | 3.88% | |||
| Gross Profit | -19.93% | 18.73% | |||
| SG&A Expenses | -8.88% | -4.30% | |||
| Depreciation & Amortization | 0.11% | -0.11% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -9.58% | -3.42% | |||
| Operating Income | -73.56% | 740.48% | |||
| Income Before Tax | -609.25% | 899.48% | |||
| Income Tax Expenses | 458.20% | 56.89% | |||
| Earnings from Continuing Operations | -604.57% | 492.48% | |||
| Earnings from Discontinued Operations | 14.81% | -56.10% | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -596.19% | 406.85% | |||
| EBIT | -73.56% | 740.48% | |||
| EBITDA | -48.26% | 288.97% | |||
| EPS Basic | -548.16% | 406.69% | |||
| Normalized Basic EPS | -364.50% | 124.60% | |||
| EPS Diluted | -1,512.39% | 178.67% | |||
| Normalized Diluted EPS | -453.82% | 132.45% | |||
| Average Basic Shares Outstanding | 10.71% | 0.04% | |||
| Average Diluted Shares Outstanding | -17.22% | -3.31% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||